VivoSeq
Other

DLBCL

7

Pipeline Programs↗

21

Active Trials↗

10

Companies Involved↗

DLBCL is an early-stage landscape with 7 programs across 10 companies. The most active players are Merck & Co., Roche, Genmab.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

75/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

PreclinicalRoche logo

Roche

1 program

PreclinicalGenmab logo

Genmab

1 program

PreclinicalJohnson & Johnson logo

Johnson & Johnson

1 program

PreclinicalTeva logo

Teva

1 program

PreclinicalA

Azurity Pharmaceuticals

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical7

Zilovertamab Vedotin

Merck & Co.

Rituximab

Roche

Gemcitabine

Johnson & Johnson

Oxaliplatin

Teva

Bendamustine

Azurity Pharmaceuticals

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody229%
Antibody–drug conjugate114%

Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

38

clinical trials

Recruiting10 · 26%
Unknown status7 · 18%
Completed6 · 16%
Active, not recruiting6 · 16%
Not yet recruiting5 · 13%
Available1 · 3%
Other3 · 8%

Clinical Trials

Trial Activity

38 trials

DALY II Japan/MB-CART2019.1 for DLBCL
Recruiting·MMiltenyi Biomedicine GmbH·Phase 2·NCT07288879·31 enrolled
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Recruiting·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT07451652·10 enrolled
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Recruiting·VVirginia Commonwealth University·Phase 2·NCT06846463·21 enrolled
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
Recruiting·MMassachusetts General Hospital·Phase 2·NCT06811272·30 enrolled
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06050694·40 enrolled
Glofitamab in Chinese Patients With R/R DLBCL
Recruiting·PPeking Union Medical College Hospital·N/A·NCT06481826·20 enrolled
Pola-ZR2P in Previously Untreated DLBCL
Recruiting·NNavy General Hospital, Beijing·Phase 2·NCT06664411·80 enrolled
AZA Combined With RCHOP in P53-mutated DLBCL.
Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06158399·52 enrolled
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Recruiting·SSun Yat-sen University·Phase 2·NCT06647940·39 enrolled
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT05139017·290 enrolled
Split-Dose R-CHOP for Older Adults With DLBCL
Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT03943901·27 enrolled
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study
Active, not recruiting·AAustin Health·Phase 1·NCT03244176·28 enrolled
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Active, not recruiting·FFujian Medical University·Phase 3·NCT03213977·475 enrolled
Copanlisib Plus Venetoclax in R/R DLBCL
Active, not recruiting·—·Phase 1/2·NCT04572763·48 enrolled
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Active, not recruiting·Novartis logoNovartis·Phase 1/2·NCT03960840·217 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)